Abeona Therapeutics Stock Shows Signs of Recovery After Key Commercial Progress
Published on 10/11/2025 at 03:18 | Redaktion boerse-global.de
After an extended period of decline, Abeona Therapeutics is demonstrating renewed momentum. The biotechnology firm is gaining traction from a significant advancement in the commercialization of its innovative gene therapy, ZEVASKYN. The critical question for investors is whether this recent positive movement can genuinely reverse the prevailing downward trend.
Despite the encouraging developments, the company’s stock continues to grapple with historical pressures. Prior to the current uptick, the shares had shed nearly 20 percent of their value over a 30-day period and were trading substantially below their 200-day moving average. Investor confidence was also tested in late September by insider share sales from CEO Vishwas Seshadri and other executives.
However, Abeona maintains a robust financial position. With $226 million in... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
